Activated Charcoal Pediatric Dose — Toxicology
Activated charcoal is a high-surface-area adsorbent agent used in the management of select acute poisonings and toxic ingestions in pediatric patients. It acts by binding ingested toxins within the gastrointestinal tract, thereby reducing systemic absorption. It is most effective when administered within 1–2 hours of ingestion and is indicated for a broad range of toxicological emergencies in children.
Pediatric Dosing
- Dose: 1–2 g/kg administered via nasogastric (NG) tube or orally (PO)
For a 20 kg child: 20 × 1 g/kg = 20 g (minimum) up to 20 × 2 g/kg = 40 g total. Consult institutional protocol for specific preparation and concentration guidance.
Avoid repeat doses of charcoal with sorbitol. If multiple-dose activated charcoal (MDAC) is indicated, subsequent doses should use charcoal without a cathartic (sorbitol-free preparations) to prevent excessive fluid and electrolyte losses.
Indications and Clinical Context
Activated charcoal is used in the acute management of potentially toxic ingestions where the substance is known to be adsorbed by charcoal and the patient presents within an appropriate time window. It is a first-line gastrointestinal decontamination strategy in pediatric toxicology, recommended by poison control guidelines for a wide variety of ingestions including medications and certain household substances. It is most beneficial when administered early; its role diminishes significantly beyond 1–2 hours post-ingestion.
Activated charcoal is not effective for all ingestions — it does not bind alcohols, iron, lithium, or caustic agents. Patient selection should involve consultation with a poison control center or toxicologist. Airway protection must be confirmed prior to administration, as aspiration is a serious risk, particularly in patients with altered mental status.
Administration and Monitoring
Activated charcoal is administered orally or via nasogastric tube. In cooperative patients, oral administration in a slurry form is acceptable; NG placement is preferred when the patient is unable or unwilling to drink the preparation. Ensure a protected airway before NG administration in any patient with reduced consciousness. Common adverse effects include vomiting, constipation, and black stools; aspiration pneumonitis is the most serious complication.
- Route: PO or NG tube
- Confirm airway patency and adequate gag reflex before administration
- Do not repeat doses with sorbitol-containing preparations — risk of hypernatremia, dehydration, and electrolyte disturbances
- Monitor for vomiting, aspiration, and bowel motility
- Consult poison control or institutional toxicology protocol for specific indications and MDAC candidacy
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.